GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (NAS:VXRT) » Definitions » Shiller PE Ratio

Vaxart (Vaxart) Shiller PE Ratio : (As of Jun. 01, 2024)


View and export this data going back to 1990. Start your Free Trial

What is Vaxart Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Vaxart Shiller PE Ratio Historical Data

The historical data trend for Vaxart's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxart Shiller PE Ratio Chart

Vaxart Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vaxart Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vaxart's Shiller PE Ratio

For the Biotechnology subindustry, Vaxart's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxart's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxart's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Vaxart's Shiller PE Ratio falls into.



Vaxart Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Vaxart's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Vaxart's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.14/131.7762*131.7762
=-0.140

Current CPI (Mar. 2024) = 131.7762.

Vaxart Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -3.190 100.560 -4.180
201409 -2.200 100.428 -2.887
201412 2.090 99.070 2.780
201503 0.330 99.621 0.437
201506 -6.050 100.684 -7.918
201509 -1.870 100.392 -2.455
201512 -1.870 99.792 -2.469
201603 -1.540 100.470 -2.020
201606 -1.980 101.688 -2.566
201609 -2.860 101.861 -3.700
201612 -2.640 101.863 -3.415
201703 -1.210 102.862 -1.550
201706 -1.650 103.349 -2.104
201709 -1.540 104.136 -1.949
201712 -0.990 104.011 -1.254
201803 0.490 105.290 0.613
201806 -1.240 106.317 -1.537
201809 -0.920 106.507 -1.138
201812 -0.690 105.998 -0.858
201903 -0.180 107.251 -0.221
201906 -0.390 108.070 -0.476
201909 -0.320 108.329 -0.389
201912 -0.130 108.420 -0.158
202003 -0.020 108.902 -0.024
202006 -0.120 108.767 -0.145
202009 -0.080 109.815 -0.096
202012 -0.130 109.897 -0.156
202103 -0.140 111.754 -0.165
202106 -0.130 114.631 -0.149
202109 -0.140 115.734 -0.159
202112 -0.170 117.630 -0.190
202203 -0.200 121.301 -0.217
202206 -0.230 125.017 -0.242
202209 -0.230 125.227 -0.242
202212 -0.180 125.222 -0.189
202303 -0.190 127.348 -0.197
202306 -0.160 128.729 -0.164
202309 -0.110 129.860 -0.112
202312 -0.120 129.419 -0.122
202403 -0.140 131.776 -0.140

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vaxart  (NAS:VXRT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Vaxart Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Vaxart's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxart (Vaxart) Business Description

Traded in Other Exchanges
Address
170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
Executives
W. Mark Watson director 324 S. HYDE PARK AVENUE, STE 350, TAMPA FL 33606
Phillip E Lee officer: Chief Financial Officer C/O VAXART, INC., 170 HARBOR WAY, STE. 300, SOUTH SAN FRANCISCO CA 94080
Elaine J Heron director 6 STONEGATE RD, PONTOLA VALLEY CA 94028
Fuad Ahmad officer: Interim CFO 461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Edward B Berg officer: SVP, General Counsel C/O VAXART, INC., 170 HARBOR WAY, STE. 300, SOUTH SAN FRANCISCO CA 94080
Robert A. Yedid director C/O LIFESCI ADVISORS, 250 WEST 55TH STREET, SUITE 3401, NEW YORK NY 10019
Margaret Echerd officer: VP, Corporate Controller, PAO 3585 MONROE STREET, SANTA CLARA CA 95051
James F. Cummings officer: Chief Medical Officer 1312 BEACHVIEW ROAD, ANNAPOLIS MD 21403
Julie M Cherrington director 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Sean Tucker officer: Chief Scientific Officer 385 OYSTER POINT BLVD., SUITE 9A, SOUTH SAN FRANCISCO CA 94080
Wouter Latour director, officer: President and Chief Executive 385 OYSTER POINT BLVD., SUITE 9A, SOUTH SAN FRANCISCO CA 94080
David E. Wheadon director C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Karen J Wilson director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Todd C Davis director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037